Results 161 to 170 of about 17,302 (216)

Venetoclax plus hypomethylating agent improves response rates but not survival in <i>TP53</i>-mutated myelodysplastic syndromes. [PDF]

open access: yesBlood Neoplasia
Canonico M   +17 more
europepmc   +1 more source

Venetoclax with azacitidine and dexamethasone: Non-cytotoxic induction therapy for T-cell leukemia and mixed-phenotype leukemia. [PDF]

open access: yesTher Adv Hematol
Lei Y   +11 more
europepmc   +1 more source

Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma. [PDF]

open access: yesBlood Neoplasia
Gordon MJ   +11 more
europepmc   +1 more source

Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study. [PDF]

open access: yesPLoS One
Ueda T   +14 more
europepmc   +1 more source

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine. [PDF]

open access: yesBlood Cancer J
Shi T   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy